2023-11-29 21:01:07
Paris (ots/PRNewswire) – Unither Pharmaceuticals, a leading CDMO company, is celebrating its 30th anniversary. In 1993, Unither Pharmaceuticals began operations by acquiring a 17-employee pharmaceutical operation that produced three dosage forms. Today, the company is the world leader in sterile unit dose manufacturing, with a production capacity of 5 billion doses and a presence on four continents. This growth is also reflected in increasing sales, which are expected to reach 500 million euros by 2023.
To view the multimedia press release please click:
Unither first used blow-fill-seal (BFS) technology in 1995 to produce sterile dosages of saline solutions, asthma medications and eye drops. From 1997, the company developed its international business, first by exporting its products, then by acquiring a factory in the United States in 2013. With the acquisition of Barretos in 2015, Unither was able to establish itself in Brazil. In 2020, the company’s global presence was further consolidated through an acquisition in Nanjing, China. In 2022, Unither further expanded its activities with the acquisition of a new ophthalmology site in São Paulo. This international development is intended to support its customers’ international production strategies by bringing the company closer to their target markets.
Since its founding, Unither has been at the forefront of innovation and continually committed to improving the quality of life for patients. Eric Goupil, President of Unither Pharmaceuticals, recalls the group’s vision: “We want to be perceived as a company that makes the healthcare solutions that improve and simplify patients’ lives available to as many people as possible.” We develop new ideas , and our enthusiasm and energy enable us to make them a reality for the benefit of our customers.”
Jean-François Hilaire, CEO at Unither Pharmaceuticals, looks to the future: “Unither’s mission is to support customers in their innovation and efforts to meet the needs of their markets. With Euroject®, the latest breakthrough in combining a single-use dosage and needle into a ready-to-use injection system, Unither underlines its commitment to simplifying the lives of doctors and patients while keeping costs under control.”
About Unither Pharmaceuticals: www.unither-pharma.com/regarding/who-are-we/
Press contact: contact@unither-pharma.com
Questions & Contact:
+33 (0)1 44 63 51 70
1701291949
#Unither #Pharmaceuticals #celebrates #years #innovation #knowhow
